In addition to inhibition of SGLT2, the improvement in hepatic steatosis and lipid synthesis may be mediated via up-regulation of PPARα1 and down-regulation of DGAT2, PPARγ1 and PPARγ2. This evidence concerns the gene SLC5A2 and fatty liver disease.